'First time this has happened': Doctors left shocked after clinical trial for cancer drug cures the disease in EVERY participant

Clinical trials for the drug dostarlimab in treating colorectal cancer have had incredible results, curing all patients of their cancer

One researcher said that it was the 'first time this has happened' in a cancer trial

Researchers say that the success of this monoclonal antibody drugis especially important for people of younger ages as cancer treatment can harm fertility

It is still too early to declare the drug a cancer cure because they trial was small and limited in scope, researchers note

June 6, 2022

"A new colorectal cancer drug has shocked researchers with how effective it is against the highly dangerous disease, as it virtually cured it in every member of a clinical trial.

Dostarlimab, a monoclonal antibody drug, smashed expectations in a recent trial run by Memorial Sloan Kettering hospital in New York, sponsored by pharmaceutical giant GlaxoSmithKline (GSK).

A year after the trial's completion, each of the 18 participants had their disease go into complete remission, with doctors unable to find signs of the cancer in their body.

While the trial was small, it is game-changing, and sets up the drug as a potential cure for one of the most dangerous common cancers known.

'I believe this is the first time this has happened in the history of cancer,' Dr Luis Diaz, one of the lead authors of the paper and an oncologist at the Memorial Sloan Kettering Cancer Center told the New York Times.

The 18 patients had all gone through previous treatments for colorectal cancer before the trial, including chemotherapy and risky surgeries.

These painful, life-altering, processes generally come with colorectal cancer, a devastating cancer diagnosis that affects 150,000 Americans every year, according to Cancer.net.

It is the third most common type of cancer in the U.S. and kills around 50,000 people every year - the second highest of any cancer.

Patients enrolled in the study received monoclonal antibody treatments every three weeks for six months.

Researchers followed up with the patients 12 months later, and the cancer had seemingly vanished from their bodies, with researchers unable to find signs of tumors with any of their available screening methods.

'At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up,' researchers wrote in the study published in the New England Journal of Medicine.

Sauce/moar (Daily Fail) :https://www.dailymail.co.uk/health/article-10890467/Doctors-left-shocked-clinical-trial-cancer-drug-cures-disease-participant.html